APA (7th ed.) Citation

Presa M, Vicente D, Calles A, Salinas-Ortega L, Naik J, García LF, & Soto J. (2023). Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain. Dove Medical Press.

Chicago Style (17th ed.) Citation

Presa M, Vicente D, Calles A, Salinas-Ortega L, Naik J, García LF, and Soto J. Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain. Dove Medical Press, 2023.

MLA (9th ed.) Citation

Presa M, et al. Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain. Dove Medical Press, 2023.